Renal Cell Carcinoma – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of renal cell carcinoma for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.
Clarivate Epidemiology’s renal cell carcinoma forecast will answer the following questions:
- In developing countries, what impact will economic growth and development have on the number of people diagnosed with renal cell carcinoma each year?
- Of all people diagnosed with renal cell carcinoma, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of renal cell carcinoma over the forecast period?
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following renal cell carcinoma populations:
- Renal cell carcinoma by stage at diagnosis
- Metastatic recurrent incident cases
- Drug-treatable populations
- Drug-treated populations
Note: Coverage may vary by country
Table of contents
- Renal Cell Carcinoma - Epidemiology - Epidemiology Dashboard
- Introduction
- Renal Cell Carcinoma Epidemiology Dashboard
- Introduction
Katie Myatt, M.S., Senior Epidemiologist, Epidemiology. Prior to joining Clarivate, Ms. Myatt worked as an epidemiologist for local and state public health departments performing infectious disease surveillance, both endemic and epidemic. Her interests are infectious disease epidemiology and cancer epidemiology. She received both her master’s degree in epidemiology and her bachelor’s degree in biology from the University of Louisville in Kentucky.
Alexandre Vo Dupuy, M.Sc., Pharm.D., is a principal epidemiologist at Clarivate. Previously, he worked in the fields of consulting and real-world evidence and at a major pharmaceutical company. He obtained his doctor of pharmacy from Descartes University in Paris and his master’s degree in pharmacoepidemiology from the University of Bordeaux. He has worked in multiple therapy areas, with a focus on cancer epidemiology. He also codeveloped a scenario-based forecast for COVID-19.